Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes

NCT00312208 is registered in ClinicalTrials.gov with Sanofi as lead sponsor.

NCT NCT00312208
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00312208 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multicenter Phase III Randomized Trial Comparing Docetaxel in Combination With Doxorubicin and Cyclophosphamide Versus Doxorubicin and Cyclophosphamide Followed by Docetaxel as Adjuvant Treatment of Operable Breast Cancer HER2neu Negative Patients With Positive Axillary Lymph Nodes
Lead sponsor
Sanofi
Phase
Phase 3
Overall status
Completed
Start date
November 30, 2001
Completion date
October 31, 2013
Enrollment
3,299 (actual)
Sites
37

Conditions

As the registry lists them; a condition with its own page is linked.

breast cancer